| 000 | 06809cam a2200829 i 4500 | ||
|---|---|---|---|
| 001 | ocn870331213 | ||
| 003 | OCoLC | ||
| 005 | 20221128212754.0 | ||
| 006 | m d | ||
| 007 | cr un||||||||| | ||
| 008 | 140516s2014 dcua obt 100 0 eng | ||
| 010 | _a 2014451576 | ||
| 040 |
_aNLM _beng _erda _epn _cNLM _dCOO _dLTSCA _dYDXCP _dE7B _dVT2 _dCOP _dMMU _dUCNAP _dN$T _dEBLCP _dDEBSZ _dOCLCO _dD6H _dOCLCA _dOCLCQ _dOCLCO _dCOCUF _dMOR _dZCU _dMERUC _dOCLCQ _dOCLCA _dOCLCO _dOCLCA _dU3W _dOCLCA _dOCLCF _dSTF _dVTS _dEZ9 _dICG _dOCLCQ _dOCLCO _dNLM _dLVT _dTKN _dDKC _dOCLCO _dAU@ _dOCLCQ _dOCLCO _dOCLCQ _dK6U _dOCLCA _dUKAHL _dOCLCO |
||
| 016 | 7 |
_a101633144 _2DNLM |
|
| 019 |
_a871260167 _a923287859 _a971083063 _a1021272863 _a1061003944 _a1061062305 _a1077380361 _a1081271153 _a1156332799 _a1228550393 _a1249253375 |
||
| 020 | _a9780309285964 | ||
| 020 | _a0309285968 | ||
| 020 | _a9780309285971 | ||
| 020 | _a0309285976 | ||
| 035 |
_a867773 _b(N$T) |
||
| 035 |
_a(OCoLC)870331213 _z(OCoLC)871260167 _z(OCoLC)923287859 _z(OCoLC)971083063 _z(OCoLC)1021272863 _z(OCoLC)1061003944 _z(OCoLC)1061062305 _z(OCoLC)1077380361 _z(OCoLC)1081271153 _z(OCoLC)1156332799 _z(OCoLC)1228550393 _z(OCoLC)1249253375 |
||
| 042 | _apcc | ||
| 043 | _aa-cc--- | ||
| 060 | 0 | 0 | _a2014 I-005 |
| 060 | 0 | 0 | _aWF 200 |
| 072 | 7 |
_aPOL _x027000 _2bisacsh |
|
| 072 | 7 |
_aPOL _x019000 _2bisacsh |
|
| 049 | _aMAIN | ||
| 100 | 1 |
_aOlson, Steve, _d1956- _eauthor. |
|
| 245 | 1 | 4 |
_aThe global crisis of drug-resistant tuberculosis and leadership of China and the BRICS : _bchallenges and opportunities : summary of a joint workshop by the Institute of Medicine and the Institute of Microbiology, Chinese Academy of Sciences _c _h[E-Book] |
| 264 | 1 |
_aWashington, D.C. : _bThe National Academies Press, _c[2014] |
|
| 300 |
_a1 online resource (1 PDF file (xxi, 195 pages)) : _billustrations |
||
| 336 |
_atext _btxt _2rdacontent |
||
| 337 |
_acomputer _bc _2rdamedia |
||
| 338 |
_aonline resource _bcr _2rdacarrier |
||
| 500 | _aTitle from PDF title page. | ||
| 504 | _aIncludes bibliographical references. | ||
| 520 | 3 | _aMultidrug-resistant tuberculosis (TB) is caused by bacteria resistant to isoniazid and rifampicin, the two most effective first-line anti-TB drugs, originally developed and introduced in the 1950 and 1960s. Since 2008, the Forum on Drug Discovery, Development, and Translation of the Institute of Medicine has hosted or co-hosted six domestic and international workshops addressing the global crisis of drug-resistant TB, with special attention to the BRICS countries - Brazil, Russia, India, China, and South Africa. The Global Crisis of Drug-Resistant Tuberculosis and Leadership of China and the BRICS is the summary of a workshop convened to address the current status of drug-resistant TB globally and in China. This report considers lessons learned from high burden countries; highlights global challenges to controlling the spread of drug-resistant strains; and discusses innovative strategies to advance and harmonize local and international efforts to prevent and treat drug-resistant TB. Additionally, the report examines the problem of MDR TB and emergent TB strains that are potentially untreatable with drugs available and considers the critical leadership role of the BRICS countries in addressing the threats and opportunities in drug-resistant TB. | |
| 536 | _aThis activity was supported by contracts between the National Academy of Sciences and Department of Health and Human Services (HHSN26300023 [Under Base #HHSN263201200074I] and Contract No. N01-OD-4-2139 TO #276; HHSF22301026T [Under Base #HHSF223200810020I]), AbbVie Inc., American Diabetes Association, American Society for Microbiology, Amgen Inc., Association of American Medical Colleges, AstraZeneca, Bristol-Myers Squibb, Burroughs Wellcome Fund, CDC Foundation, Celtic Therapeutics, LLLP, Critical Path Institute, Doris Duke Charitable Foundation, Eli Lilly & Co. Foundation, Eli Lilly and Company, FasterCures, Fondation Merieux, Friends of Cancer Research, GlaxoSmithKline, Johnson & Johnson, March of Dimes Foundation, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc., and Sanofi. The views presented in this publication do not necessarily reflect the views of the organizations or agencies that provided support for the activity. | ||
| 588 | 0 | _aVersion viewed June 30, 2014. | |
| 505 | 0 | _aThe challenges and opportunities for the BRICS countries to lead -- Catching up with the microbe -- Drug-resistant TB in China -- Experiences with MDR TB in other countries -- Drug-resistant tuberculosis in pediatric populations -- Global perspectives on transmission and infection control -- Rapid diagnostic technologies : status and limitations -- Addressing diagnosis and treatment across the spectrum of drug resistance -- Developing and strengthening the drug supply chain for drug-resistant TB -- Embracing a new vision for research -- What will be required to achive zero deaths from TB? -- Creating an evidence-based blueprint for action. | |
| 590 | _aWorldCat record variable field(s) change: 650 | ||
| 650 | 0 |
_aMultidrug-resistant tuberculosis _vCongresses. |
|
| 650 | 0 |
_aMultidrug-resistant tuberculosis _xPrevention _vCongresses. |
|
| 650 | 0 |
_aTuberculosis _vCongresses. |
|
| 650 | 0 |
_aDrug resistance _vCongresses. |
|
| 650 | 0 | _aMultidrug-resistant tuberculosis. | |
| 650 | 0 |
_aAntitubercular agents. _95248 |
|
| 650 | 0 | _aWorld health. | |
| 650 | 0 | _aInternational cooperation. | |
| 650 | 1 | 2 | _aTuberculosis, Multidrug-Resistant |
| 650 | 2 | 2 |
_aAntitubercular Agents _95248 |
| 650 | 2 | 2 | _aGlobal Health |
| 650 | 2 | 2 | _aInternational Cooperation |
| 651 | 2 | _aChina | |
| 700 | 1 |
_aEnglish, Rebecca A., _eauthor. |
|
| 700 | 1 |
_aClaiborne, Anne B., _eauthor. |
|
| 710 | 2 |
_aInstitute of Medicine (U.S.). _bForum on Drug Discovery, Development, and Translation, _eissuing body. |
|
| 710 | 2 |
_aInstitute of Medicine (U.S.), _esponsoring body. |
|
| 710 | 2 |
_aZhongguo ke xue yuan. _bWei sheng wu yan jiu suo, _esponsoring body. |
|
| 711 | 2 |
_aGlobal Crisis of Drug-Resistant Tuberculosis and Leadership of the BRICS Countries : Challenges and Opportunities (Workshop) _d(2013 : _cBeijing, China) |
|
| 856 | 4 | 0 |
_uhttps://search.ebscohost.com/login.aspx?custid=ns123844&authtype=ip,shib&direct=true&scope=site&db=nlebk&db=nlabk&AN=867773 _yKingston Hospital NHS Foundation Trust OpenAthens account holders click here for access |
| 938 |
_aAskews and Holts Library Services _bASKH _nAH36561400 |
||
| 938 |
_aAskews and Holts Library Services _bASKH _nAH36617758 |
||
| 938 |
_aProQuest Ebook Central _bEBLB _nEBL3379093 |
||
| 938 |
_aebrary _bEBRY _nebr10863741 |
||
| 938 |
_aEBSCOhost _bEBSC _n867773 |
||
| 938 |
_aYBP Library Services _bYANK _n11575900 |
||
| 938 |
_aYBP Library Services _bYANK _n11864833 |
||
| 942 | _n0 | ||
| 994 |
_a92 _bN$T |
||
| 999 |
_c91994 _d91994 |
||